肿瘤坏死因子诱导凋亡配体(TRAIL)抗肿瘤治疗研究进展  

Progress on the antitumor effect of TNF related apoptosis inducing ligand(TRAIL)

作　　者：胡璧[1] 王建军[1] 徐根兴 

机构地区：[1]南京大学生命科学院南京大学公共健康医学中心,南京210093 [2]江苏省基因药物工程技术研究中心,苏州215128

出　　处：《药学与临床研究》2008年第3期194-200,共7页Pharmaceutical and Clinical Research

基　　金：国家科技部836项目(编号2006AA02Z19E)

摘　　要：癌症是全球死亡率最高的疾病。严重影响了癌症患者的生活质量。细胞凋亡又称程序化细胞死亡,是多细胞有机体为调控机体发育、维护内环境稳定、由基因控制的细胞主动死亡过程。许多研究表明,肿瘤坏死因子诱导凋亡配体(TRAIL)能通过与死亡受体结合选择性引起肿瘤细胞凋亡而对正常细胞无明显影响,有望成为一种新的抗肿瘤制剂。本文就近几年TRAIL抗肿瘤研究的进展作一综述。Cancer has severe effect on life equality of people as the most fatal disease. Apoptosis, also called programmed cell death, is a gene-controlled initiative cell death process which is responsible for regulation of development and maintenance of homeostasis in organisma multicellularis. More and more studies revealed that TNF related apoptosis inducing ligand （TRAIL） induced apoptosis through the death receptors DR4 and/or DR5 in various cancer cell lines without appreciable effect in normal cells, and it can be a promising candidate for cancer therapy. The recent progress on the antitumor effect of TRAIL were reviewed and summarized.

关 键 词：TRAIL 死亡受体 抗肿瘤作用 凋亡 

分 类 号：R730.5[医药卫生—肿瘤]